All notes

3 min readInvestment focus

Biotech seed and pre-seed investment at Variance Ventures

Explore Variance Ventures’ biotech focus, from computational biology to lab automation, and what to include in a seed or pre-seed pitch.

By Variance Ventures

Biotechnology is one of Variance Ventures’ six investment sectors. Our interest centers on the convergence of biology and computation: computational drug discovery, protein and molecular design, synthetic biology, and the lab automation and data platforms that support experimental work.

We invest at pre-seed and seed, primarily in the United States while considering founders globally. A typical initial investment is around $50,000, with flexibility. That describes the approximate size of our participation, rather than the amount an entire biotech round should raise.

For founders looking for biotech seed investors, fit depends on the scientific problem, the business being built around it, and the evidence the next round can produce. A software platform for laboratories and a company developing a therapeutic can both work with biological data, yet need very different investors and financing plans.

Where biology and computation meet

Our investment overview describes the areas above. Within those areas, a useful introduction explains the bottleneck before explaining the technology.

For computational discovery, that might be the difficulty of identifying useful candidates under a particular set of experimental constraints. For molecular design, it might be the cost of testing designs that satisfy several competing requirements. For lab automation, it might be a workflow whose manual steps produce inconsistent records or limit throughput.

These are illustrative problems, rather than a list of projects we have funded. The same distinction matters in your pitch: a plausible application is different from a demonstrated capability.

Explain the learning loop

A model architecture becomes more meaningful when an investor can follow the loop from data to prediction to experiment and back again.

Describe where the starting data comes from, what rights the company has to use it, and which parts of the workflow generate new information. Explain how you distinguish a prediction that looks promising from a result that survives experimental testing. If experiments are outsourced, show how that affects cost, scheduling, access to underlying records, and the ability to repeat a result.

An illustrative lab platform might improve the consistency of one assay workflow before expanding to others. A useful pitch would report the original workflow, the conditions tested, the failure cases, and the repeatability of the improvement. A faster demonstration alone would leave several of those questions unanswered.

Connect the science to a first business

“Platform” can describe a technical capability without explaining who will buy it. Tell us the first customer, the decision that customer needs to make, and why your product changes that decision.

If the route is software or research tools, explain deployment, procurement, support requirements, and how customers evaluate value. If the route involves licensing or partnerships, separate exploratory discussions from signed agreements. For a therapeutic program, explain the intended development path and the expertise needed to assess it; an early computational result does not establish clinical performance.

The initial market can be narrow. A credible first workflow is more informative than adding together every industry that might someday use the underlying technology.

Match the round to a specific uncertainty

An early biotech financing plan should identify what the capital lets the team learn. That could involve reproducing a result, testing a system outside the founding lab, or establishing that an external customer can use a tool without extensive founder involvement.

Our biotech milestone planning guide explains how to connect that evidence to a budget and timeline. Include dependencies such as samples, laboratory access, data licenses, intellectual property agreements, and specialist hires. Explain what happens if a critical experiment is delayed or produces a negative result.

Finding the right capital partners

Our biotech investor guide covers several different approaches to early biology investing. Consider whether you need a specialist lead, a laboratory program, smaller participants, or a combination. Our guide to micro VCs and small checks explains how a roughly $50,000 investment can fit into a broader round.

To introduce your company, follow how to pitch Variance Ventures. Send the biological problem, technical approach, team background, current evidence, and capital requirements. Describe the limits of the evidence as clearly as its promise, so the first conversation can focus on what the company needs to prove next.